Abstract: Hyperbaric oxygen therapy (HBOT) involves the inhalation of 100 percent oxygen at pressures greater than at sea level. One of the most common indications for HBOT is to aid healing of diabetic foot wounds. All cases of diabetic foot wounds that were seen by...
Diabetes
Procalcitonin as a diagnostic aid in diabetic foot infections.
Abstract: The diagnosis of diabetic foot infection (DFI) is usually a challenge to the clinician. Procalcitonin (PCT), a 116-amino acid propeptide of calcitonin, is a new marker of bacterial infections and sepsis. We evaluated the serum value of PCT as a marker of...
Extracorporeal shockwave treatment for chronic diabetic foot ulcers.
Abstract: This prospective study compared extracorporeal shockwave treatment (ESWT) with hyperbaric oxygen therapy (HBO) in chronic diabetic foot ulcers. Seventy-two patients with 72 chronic diabetic foot ulcers were randomly divided into two groups of similar...
The clinical and economic potential of hyperbaric oxygen therapy in the treatment of diabetic ulceration and other conditions.
Abstract: Selective use of systemic hyperbaric oxygen therapy (HBOT) is a treatment that deserves further study and analysis. The current situation in the United Kingdom (UK) is discussed in relation to available evidence and practices elsewhere. It would appear that...
Development of underwater and hyperbaric medicine in Malaysia.
Abstract: Underwater and Hyperbaric Medicine is a treatment modality gaining recognition in Malaysia. It uses the hyperbaric oxygen therapy (HBOT) approach where patients are placed in recompression chambers and subjected to oxygen therapy under pressure. In Malaysia...
Bioengineered alternative tissues and hyperbaric oxygen in lower extremity wound healing.
Abstract: With the advent and clinical application of recombinant chemical and cellular mediators of wound healing and a better understanding of the importance of serial debridement, most foot wounds can be healed with little morbidity. Despite these advances, there...
Factors influencing the outcome of lower-extremity diabetic ulcers treated with hyperbaric oxygen therapy.
Abstract: The objectives of this study were to report outcomes of a large number of patients receiving hyperbaric oxygen therapy (HBO(2)T) for diabetic lower-extremity ulcers, and to identify likely outcome predictors. Five hyperbaric facilities supplied data on 1,006...
Clinical Trial – Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers
Diabetic foot ulcers are a major cause of morbidity and mortality, accounting for
approximately two-thirds of all non-traumatic amputations performed in the United States. The
cost of foot ulcers in diabetic patients averages almost $28,000 for the two years after
diagnosis of the ulcer. Hyperbaric oxygen (HBO) serves as primary or adjunctive therapy for a
diverse range of medical conditions. HBO also has been used as an adjunct to antibiotics,
debridement, and revascularization in the therapy of chronic, nonhealing wounds associated
with diabetes or non-diabetic vascular insufficiency.
The aim of the study is to assess whether hyperoxia induced angiogenesis in diabetic patients
with foot ulcers.
[Hyperbaric oxygen therapy for chronic diabetic wounds of the lower limbs–a review of the literature].
Abstract: Chronic wounds of the lower limbs are a cause of severe morbidity in diabetic patients. Low oxygen tension around the wound is one of several critical factors, which mutually enhance the progression of a chronic ulcer. Hyperbaric oxygen therapy (HBO) is...
Clinical Trial – Hyperbaric Oxygen, Oxidative Stress, NO Bioavailability and Tissue Oxygenation
Hyperbaric oxygen therapy (HBOT) increases tissue oxygenation and serves as an adjunct
therapy for diabetic wounds. However, some patients have insufficient increase or even
paradoxical decrease in tissue O2 due to vasoconstriction. The aim of the present study was
to investigate the pathophysiology responsible for the different consequences of HBOT and to
evaluate the effect of N-acetylcysteine (NAC) on these changes.
Methods: Prospective, randomized, cross-over trial including fifty diabetic patients with
non-healing ulcers. All patients had two HBOT (100%oxygen, 2ATA) with NAC at the first or the
second evaluation. At the beginning and at the end of each evaluation, ulcer oxygenation and
plasma levels of malondialdehyde (MDA), total anti-oxidant status (TAOS) and nitric oxide
(NO) were measured. Patients with ulcer oxygenation above 200mmHg, were subjected to complete
HBOT protocol.